课题基金 / 基金详情

Phosphoprotein phosphatase 2A, a new target for Alzheimer's Disease interventio

Phosphoprotein phosphatase 2A, a new target for Alzheimer's Disease interventio
磷蛋白磷酸酶2A,阿尔茨海默病干预新靶点
批准号:
7998103
负责人:
Steven P. Braithwaite
金额:
$32.47万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-15 至 2012-07-31

项目摘要

项目成果

Steven P. Braithwaite的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):tau蛋白的异常过度磷酸化在阿尔茨海默病(AD)和其他tau蛋白病中起重要作用。目前集中于tau激酶(例如GSK-3、MAPK、cdk 5、CK-1、PKA、CaMKII)的治疗方法受到多重和冗余tau磷酸化途径的阻碍。相比之下,蛋白磷酸酶-2A(PP 2A)是主要的tau磷酸酶,占tau去磷酸化的约70%,并且最近的研究表明其表达和活性在AD中下调。PP 2A活性受可逆的羧基甲基化控制,因此抑制去甲基化可能是恢复健康tau磷酸化水平的有希望的干预策略。围绕这一假设构建筛选平台,我们鉴定了小分子SIG 1012,其以剂量依赖性方式降低N2 a细胞中的p-tau水平,并且口服有效降低野生型小鼠中的p-tau。初步药理学数据表明,SIG 1012具有非常有利的安全性和毒理学特征。拟议的I期研究计划对于验证PP 2A作为小分子有效干预AD的药物靶标至关重要。它概述了在AD动物模型中进行有效性概念验证研究的具体步骤。关键的3xTg-AD小鼠和(AAV)-I2 CTF大鼠实验将与世界知名的tau蛋白在神经退行性疾病中的作用专家Khalid Iqbal博士合作进行。这项研究提案的成功完成将导致在第二阶段正式临床前开发的SIG 1012作为“一流的”PP 2A调节剂治疗AD和其他tau蛋白病。) 公共卫生相关性:阿尔茨海默氏病(AD)是一种进行性和致命的脑部疾病,目前困扰着超过500万美国人和全球超过2700万人。目前AD的治疗在很大程度上是不令人满意的,更有效的疗法的开发代表了巨大的未满足的医疗需求。这类新型磷蛋白调节剂的成功开发将为患有AD的人提供重要的额外且可能更好的治疗选择。
英文摘要
DESCRIPTION (provided by applicant): Abnormal hyperphosphorylation of tau plays an important role in Alzheimer's disease (AD) and other tauopathies. Current therapeutic approaches with focus on tau kinases (e.g. GSK-3, MAPK, cdk5, CK-1, PKA, CaMKII) are hindered by multiple and redundant tau phosphorylation pathways. In contrast, protein phosphatase-2A (PP2A) is the major tau phosphatase accounting for ~70% of tau dephosphorylation, and recent research shows that its expression and activity are down-regulated in AD. PP2A activity is governed by reversible carboxyl-methylation, thus inhibiting demethylation might be a promising intervention strategy to restore healthy tau phosphorylation levels. Building a screening platform around this hypothesis, we identified a small molecule SIG1012, which reduces p-tau levels in N2a cells in a dose-dependent manner and is orally efficacious in reducing p-tau in wild type mice. Preliminary pharmacological data suggests that SIG1012 has highly favorable safety and toxicology profiles. The proposed Phase I research plan is critical to validating PP2A as a pharmaceutical target for effective intervention in AD by a small molecule. It outlines specific steps for the proposed proof of concept studies of efficacy in animal models of AD. The critical 3xTg-AD mouse and (AAV)-I2 CTF rat experiments will be carried out in collaboration with Dr. Khalid Iqbal, a world- renowned expert on the role of tau in neurodegenerative diseases. Successful completion of this research proposal will lead in Phase II to formal preclinical development of SIG1012 as the "first-in-class" PP2A modulating agent for treatment of AD and other tauopathies. ) PUBLIC HEALTH RELEVANCE: Alzheimer's disease (AD) is a progressive and fatal brain disease that afflicts over 5 million Americans today and over 27 million people worldwide. Current treatments of AD are largely unsatisfactory and development of more effective therapies represents a great unmet medical need. Successful development of this novel class of phosphoprotein modulators will provide an important additional, and potentially better, therapeutic option for people suffering from AD.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.4155/fmc.11.47
发表时间: 2011-05
期刊: Future medicinal chemistry
影响因子: 4.2
作者: [Voronkov M, Braithwaite SP, Stock JB]
通讯作者: Stock JB
TARGETING INFLAMMATION USING SALSALATE FOR TYPE 2 DIABETES (TINSAL-T2D)
  • 批准号:
    7716891
  • 项目类别:
  • 资助金额:
    $0.21万
  • 财政年份:
    2008
  • 负责人:
    Steven P. Braithwaite
  • 依托单位:
海外基金